[Skip to Content]

Upstate Active Clinical Trials

Study Title:

ACNS1723 - A Phase 2 Study of Dabrafenib (NSC#763760) with Trametinib (NSC#763093) after Local Irradiation in Newly Diagnosed
BRAFv600 - Mutant High-Grade Glioma (HGG) (IND #145355)

What is the purpose of the study? (in Layman's terms, please describe the study)

Study for newly diagnosed High-grade glioma with BRAFv600 mutant tumors

Upstate Institutional Review Board (IRB) Number:

1510386

Study/Protocol ID:

ACNS1723

Study Phase:

II

Patient Age Group:

Children

Principal Investigator:

Melanie A Comito

Who is eligible?

< or = 25 years of age

What is involved if I participate?

  • How long is the study?
    2 years
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No
  • What tests and procedures are involved?
    Standard of care study

Where will the study take place?

Cancer center

Other Information:

None

Who can I contact for more information?

Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]

Return to Previous Page || Search Again

Top